Wells Fargo analyst Brandon Couillard has lowered the price target for Waters Corp (WAT) to $355 from a previous $415, while maintaining an 'Equal-Weight' rating. This adjustment follows similar moves by other major financial institutions, including BofA Securities and UBS, which have also recently trimmed their targets for the stock. The collective downward revisions suggest a more cautious outlook among analysts regarding the company's valuation in the current climate. Meanwhile, Waters Corp remains focused on its planned merger with the life science and diagnostics business of BD, a strategic move aimed at strengthening its market position. Investors are closely watching how these revised analyst expectations will impact the stock's performance amid ongoing corporate developments. The overall sentiment remains tempered despite the company's ongoing expansion initiatives and pending merger.
Get AI-powered deep analysis for every story with a paid subscription
Upgrade for Analysis